Lindsey Roeker, MD

home / authors / lindsey-roeker-md

Articles

Lindsey Roeker, MD, Discusses Potential for BTK Inhibition Plus Umbralisib/Ublituximab in CLL

January 17th 2022

Lindsey Roeker, MD, spoke about identifying the correct population of patients with chronic lymphocytic leukemia who will benefit from umbralisib and ublituximab plus ibrutinib.

Lindsey Roeker, MD, Discusses the Outcomes of Using Ibrutinib With Umbralisib/Ublituximab in CLL

Lindsey Roeker, MD

January 9th 2022

Lindsey Roeker, MD, spoke about phase 2 trial results which demonstrated efficacy of the combination of umbralisib and ublituximab added to ibrutinib for patients with chronic lymphocytic leukemia.

Lindsey Roeker, MD, Discusses Rationale for Investigating an Ibrutinib-Containing Triplet in CLL

Lindsey Roeker, MD

January 3rd 2022

Lindsey Roeker, MD, spoke about using a combination that includes a Bruton tyrosine kinase inhibitor, PI3K inhibitor, and an anti-CD20 monoclonal antibody for patients with chronic lymphocytic leukemia.

Lindsey Roeker, MD, Discusses Which Data From ASH 2021 Have the Biggest Potential to Impact Care

Lindsey Roeker, MD

December 23rd 2021

Lindsey Roeker, MD, spoke about data presented at ASH 2021 and what she thought to be most interesting.